Vasculitis & polymyalgia rheumatica
Phase-Specific Healthcare Costs Associated With Giant Cell Arteritis in Ontario, Canada
Authors' conclusion
A diagnosis of GCA was associated with increased healthcare costs during all 3 phases of care.
Study context
- Population
- Newly diagnosed giant cell arteritis (GCA) aged ≥ 66 years, Ontario, Canada, 2002–2017; median age 77 (IQR 72–82) years, 68.2% femalematched cohort
- Participants
- 6,730 vs 40,380
- Exposure
- Newly diagnosed GCA vs matched non-GCA comparators
- GCAn = 6,730
- Non-GCA comparatorsn = 40,380reference
- Outcome
- Additional healthcare system costs associated with GCA (2021 Canadian dollars (CAD)) in the 1-year prediagnosis, 1-year postdiagnosis and ongoing phases
Methodological detailshealth administrative data, propensity-score matched 1:6, Follow-up until death, outmigration, or March 31, 2020
- Health administrative data
- Propensity-score matched 1:6
- Follow-up until death, outmigration, or March 31, 2020
Main finding
As reported in the abstract
Increased healthcare cost per patient, GCA vs comparators (2021 CAD)
Increased cost, 1-year prediagnostic period
6619.4 CAD $ per patient
95% CI 5964.9–7274.0
GCA
Increased cost, 1-year postdiagnostic phase
12,150.3 CAD $ per patient (95% CI 11,233.1–13,067.6)
GCA
Increased cost, ongoing care for year 3 onward
20,886.2 CAD $ per patient (95% CI 17,195.2–24,577.2)
GCA
Observational data: associations, not effects.
Original publication
Phase-Specific Healthcare Costs Associated With Giant Cell Arteritis in Ontario, Canada. J Rheumatol. Published 1 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →